Sugi Predict

Sugi Predict / Compounds / SCHEMBL4486457

SCHEMBL4486457

SCHEMBL4486457

N#Cc1cccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)c(F)c2)c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 13/20 0.75
▸ FLT3 P36888 10/20 0.75
▸ KIT P10721 10/20 0.75
▸ MAP4K4 O95819 7/20 0.58
▸ AXL P30530 7/20 0.58
▸ LIMK1 P53667 7/20 0.58
▸ CSNK1G2 P78368 7/20 0.58
▸ MAP4K2 Q12851 7/20 0.58
▸ STK3 Q13188 7/20 0.58
▸ CAMK2G Q13555 7/20 0.58
▸ CAMK2D Q13557 7/20 0.58
▸ HIPK4 Q8NE63 7/20 0.58
▸ SLK Q9H2G2 7/20 0.58
▸ CLK4 Q9HAZ1 7/20 0.58
▸ MKNK2 Q9HBH9 7/20 0.58
▸ LCK P06239 7/20 0.58
▸ PLK4 O00444 6/20 0.58
▸ MARK3 P27448 6/20 0.58
▸ MARK2 Q7KZI7 6/20 0.58
▸ MAP3K20 Q9NYL2 6/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4468205 0.88 KDR (0.74) KDRFLT3KITMAP4K4AXL
SCHEMBL4466145 0.86 KDR (0.79) KDRFLT3KITMAP4K4AXL
SCHEMBL4481371 0.86 KDR (1.00) KDRFLT3KITMAP4K4AXL
SCHEMBL4466205 0.84 KDR (0.77) KDRFLT3KITMAP4K4AXL
SCHEMBL4719549 0.82 PLK4 (0.74) KDRFLT3KITMAP4K4AXL
SCHEMBL4477226 0.82 KDR (0.85) KDRFLT3KITMAP4K4AXL
SCHEMBL4480734 0.80 KDR (0.75) KDRFLT3KITMAP4K4AXL
SCHEMBL4485286 0.79 KDR (0.80) KDRFLT3KITMAP4K4AXL
SCHEMBL4486498 0.78 KIT (0.82) KDRFLT3KITMAP4K4AXL
SCHEMBL4477423 0.77 KDR (0.78) KDRFLT3KITMAP4K4AXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1487841-B1 THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS ABBVIE INC (US) 2014-01-15 — — EP disclosed
US-7560552-B2 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES (US) 2009-07-14 — — US disclosed
US-20060276490-A1 Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors MICHAELIDES MICHAEL R 2006-12-07 — — US disclosed
US-20040014756-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBVIE INC. 2004-01-22 — — US disclosed
US-20030225273-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES 2003-12-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014756-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK KDR 425/4885FLT3 29/4885KIT 394/4885
US-20060276490-A1 Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors ABL1, LCK, ERBB2 KDR 391/4885FLT3 16/4885KIT 361/4885
US-20030225273-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK KDR 425/4885FLT3 29/4885KIT 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.